Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Syntaxin-17 (STX17) is a tail-anchored Qa-SNARE (soluble NSF attachment protein receptor) protein with a pivotal role in mammalian macroautophagy, especially in mediating membrane fusion between autophagosomes and lysosomes to form autolysosomes and thus enable degradation and recycling of cytosolic material[1][3][4]. STX17 contains an N-terminal Habc domain, a Qa-SNARE motif, and two unique tandem transmembrane domains that anchor it to autophagosomal membranes[1][4]. Upon autophagy induction, STX17 is recruited from the cytosol or Golgi to mature autophagosomes, where, in concert with autophagic SNAREs SNAP29 (Qbc-SNARE) and VAMP8 (R-SNARE), it forms a SNARE complex that fuses autophagosomes to lysosomes[1][4]. STX17 also interacts with proteins such as members of the ATG8 family (notably GABARAP), FIP200, and ATG13, and its function is regulated by phosphorylation (notably by TBK1 at serine 202) and by the microtubule-associated protein MAP1B-LC1[2][5]. In addition to its canonical role in membrane fusion during autophagy, STX17 has regulatory roles in autophagy initiation, potential roles in mitochondrial division (through Drp1 recruitment), and lipid droplet dynamics in some species and cell types[3][5]. Defects in STX17-mediated autophagy are implicated in neurodegenerative and age-related diseases, although STX17 itself is not currently a direct drug target and is not established as a clinical biomarker[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Syntaxin-17 (STX17).